Ignite Creation Date:
2024-05-06 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 12:50 PM
Study NCT ID:
NCT03600350
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-09
First Post:
2018-07-11
Brief Title:
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety of an investigational DNA vaccine pTVG-HP a plasmid DNA encoding human prostatic acid phosphatase PAP in combination with nivolumab and the efficacy of this combination in decreasing serum Prostate-Specific Antigen PSA in patients with non-metastatic non-castrate prostate cancer clinical stage D0M0
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-0418 | OTHER | None | None |
| A534260 | OTHER | None | None |
| SMPHMEDICINEHEM-ONC | OTHER | None | None |
| NCI-2018-01474 | REGISTRY | None | None |
| Protocol Version 4152024 | OTHER | UW Madison | None |